1. Home
  2. MRSN vs BCG Comparison

MRSN vs BCG Comparison

Compare MRSN & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRSN
  • BCG
  • Stock Information
  • Founded
  • MRSN 2001
  • BCG 2016
  • Country
  • MRSN United States
  • BCG United States
  • Employees
  • MRSN N/A
  • BCG N/A
  • Industry
  • MRSN Biotechnology: Pharmaceutical Preparations
  • BCG
  • Sector
  • MRSN Health Care
  • BCG
  • Exchange
  • MRSN Nasdaq
  • BCG Nasdaq
  • Market Cap
  • MRSN 37.0M
  • BCG 32.5M
  • IPO Year
  • MRSN 2017
  • BCG N/A
  • Fundamental
  • Price
  • MRSN $7.15
  • BCG $1.69
  • Analyst Decision
  • MRSN Strong Buy
  • BCG
  • Analyst Count
  • MRSN 3
  • BCG 0
  • Target Price
  • MRSN $33.00
  • BCG N/A
  • AVG Volume (30 Days)
  • MRSN 62.6K
  • BCG 24.3K
  • Earning Date
  • MRSN 11-12-2025
  • BCG 11-13-2025
  • Dividend Yield
  • MRSN N/A
  • BCG N/A
  • EPS Growth
  • MRSN N/A
  • BCG N/A
  • EPS
  • MRSN N/A
  • BCG N/A
  • Revenue
  • MRSN $34,769,000.00
  • BCG $173,961,000.00
  • Revenue This Year
  • MRSN N/A
  • BCG N/A
  • Revenue Next Year
  • MRSN N/A
  • BCG N/A
  • P/E Ratio
  • MRSN N/A
  • BCG N/A
  • Revenue Growth
  • MRSN 16.14
  • BCG 7.45
  • 52 Week Low
  • MRSN $5.21
  • BCG $1.45
  • 52 Week High
  • MRSN $70.75
  • BCG $6.55
  • Technical
  • Relative Strength Index (RSI)
  • MRSN 47.47
  • BCG 41.63
  • Support Level
  • MRSN $7.04
  • BCG $1.75
  • Resistance Level
  • MRSN $7.49
  • BCG $2.10
  • Average True Range (ATR)
  • MRSN 0.44
  • BCG 0.14
  • MACD
  • MRSN 0.00
  • BCG -0.02
  • Stochastic Oscillator
  • MRSN 36.53
  • BCG 36.92

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

About BCG Binah Capital Group Inc. Common Stock

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

Share on Social Networks: